Biotech Startups

Dimericon Therapeutics is a biotech company developing crosslinked helix dimers ("Dimericons") as therapeutics and as templates for small-molecule development, targeting hard-to-drug intracellular protein-protein interactions. Its lead program focuses on hematological malignancies, with a seed round supporting preclinical work toward an IND-ready clinical candidate.

1 investor

Oak Hill Bio develops therapies for patients with rare diseases, supported by experienced life science investors.

1 investor

1 investor

Oban Biopharma develops allosteric GPCR-targeted therapeutics for metabolic and CNS/neuropsychiatric diseases, using computational structural and chemotype analysis combined with AI-based druggability filters to identify drug candidates. Its pipeline focuses on allosteric modulators of clinically validated GPCR targets intended to offer efficacy with fewer side effects than traditional orthosteric drugs.

1 investor

Obulytix develops Precision Lysin Therapeutics, a novel class of engineered biologics designed to target multidrug-resistant Gram-negative bacteria for severe bloodstream and lung infections. The company was founded as a spin-off from Ghent University and KU Leuven to address antimicrobial resistance in healthcare.

1 investor

Oceanium develops proprietary seaweed-based ingredients for food, health, and materials using innovative biorefinery and green chemistry processes. The company serves the food, health, and materials industries while advancing ocean health and coastal sustainability across the Western Hemisphere.

1 investor

Octarine Bio is a synthetic biology platform company that engineers microorganisms to produce bio-based, low-impact ingredients and materials to replace unsustainable synthetic chemical processes across industries including pharmaceuticals, chemicals, food, and energy. Founded in 2018 based on research from Danish universities, the company applies precision fermentation and enzymatic enhancement to develop commercial-scale bio-manufacturing solutions.

1 investor

1 investor

Ocutec is a life sciences company developing advanced materials and technologies for contact lenses and ophthalmic applications. It works in the medical device and biomaterials space.

1 investor

Ocutheia offers biotechnology consulting services with expert biotechnologists providing tailored solutions to clients.

1 investor

Ohmic Biosciences develops engineered proteins and synthetic biology solutions to address diseases in crops. The company creates durable treatments applicable across different agricultural products.

1 investor

OIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.

1 investor

Ojer Pharma develops pharmaceutical and cosmetic products for treating skin conditions and infections in human and veterinary markets. The company offers prescription medications, over-the-counter treatments, and dermatological cosmetics addressing conditions ranging from bacterial skin infections to actinic keratosis and herpes simplex.

1 investor

Okami Medical develops the LOBO vascular occlusion system, an occluder built on high-density, small-pore HDBRAID technology for fast arterial occlusion in the peripheral vasculature, along with SENDERO microcatheters and delivery catheters. Its products are intended for physicians treating peripheral vascular conditions.

1 investor

Okanagan Specialty Fruits uses biotechnology to develop fruit varieties aimed at more efficient and sustainable food production. The company operates in the agricultural biotechnology space.

1 investor

Okava develops medicines for dogs and cats by adapting established human pharmaceuticals for veterinary use, targeting conditions such as obesity, diabetes, arthritis, and chronic inflammation. The company operates in the animal health and pet pharmaceutical sector.

1 investor

Olatec develops a pharmaceutical platform targeting acute and chronic inflammatory diseases, with its lead compound dapansutrile (OLT1177), a NLRP3 inhibitor currently in Phase 2 clinical trials in the US and Europe.

1 investor

1 investor

Oleos operates a biomanufacturing platform that converts non-edible biomass waste into low-carbon fuel feedstocks, including cellulosic sugars and renewable oils (triacylglycerols). These feedstocks are used to produce advanced fuels such as ethanol, renewable diesel, and sustainable aviation fuel via HEFA and alcohol-to-jet pathways.

1 investor

Olfactive Biosolutions develops Pivit, a product platform that applies receptor science to consumer food and beverage products by translating natural food molecules into targeted physiological outcomes.

1 investor

Olfera develops biopharmaceutical treatments for neurological conditions that use the olfactory system as a non-invasive pathway to the brain, bypassing the blood-brain barrier. Its platform is used to discover, optimize, and deliver drugs, converting existing FDA-approved and candidate neurological drugs into easier-to-administer therapies.

1 investor

Oligon Therapeutics develops RNA-based multi-targeting drugs using its SeekR platform, which combines RNA aptamer oligo-binders with siRNA silencers into a single self-delivering molecule for precise targeting of specific cell types, including T-cells and cancer cells. The biotechnology company applies AI-based molecular modeling to discover and optimize these RNA drug candidates.

1 investor

Oligotune is developing RNA-based cancer immunotherapy treatments that target solid tumours with enhanced precision. The company uses a data-driven pre-clinical R&D pipeline to address mechanisms in cancer immunotherapy that existing treatments do not adequately target.

1 investor

Olive Capital is a seed-stage venture capital firm that invests in founders building in synthetic biology, software, and emerging platforms.

1 investor